Shinsuke Toba

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · Journal of Medicinal Chemistry · 2022 · 590 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

<i>In Vitro</i> Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito, Takafumi Sato, Merime Ota et al. · Antimicrobial Agents and Chemotherapy · 2017 · 378 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells

Michihito Sasaki, Kentaro Uemura, Akihiko Sato et al. · PLoS Pathogens · 2021 · 213 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

<i>In Vivo</i> Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models

Rio Nakamura, Tsukasa Ito-Horiyama, Miki Takemura et al. · Antimicrobial Agents and Chemotherapy · 2019 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters

Michihito Sasaki, Koshiro Tabata, Mai Kishimoto et al. · Science Translational Medicine · 2022 · 99 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17